Bristol Myers Squibb (BMY) EBT (2009 - 2026)

Bristol Myers Squibb (BMY) has reported EBT for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 130.46% year-over-year to $4.1 billion in Q2 2026; TTM through Jun 2026 was $11.9 billion, a 80.59% increase from a year earlier, with the FY2025 full-year figure at $9.3 billion, up 211.33% from the prior year.
• EBT was $4.1 billion for Q2 2026 at Bristol Myers Squibb, up from $3.2 billion in the prior quarter.
• Over five years, EBT peaked at $4.1 billion in Q2 2026 and troughed at -$11.5 billion in Q1 2024.
• A 5-year average of $1.4 billion and a median of $1.9 billion in 2022 frame the typical range for EBT.
• Across the five-year window, EBT sank 515.74% in 2024 and jumped 740.0% in 2025, its largest moves.
• Over 5 years, EBT stood at $1.9 billion in 2022, then fell by 9.95% to $1.7 billion in 2023, then slumped by 89.55% to $175.0 million in 2024, then jumped by 740.0% to $1.5 billion in 2025, then jumped by 177.96% to $4.1 billion in 2026.
• The last three EBT figures came in at $4.1 billion (Q2 2026), $3.2 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.